title: Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study.
abstract: BACKGROUND
  Kaposi's sarcoma (KS) is a potentially life-threatening multifocal neoplasm. Despite the significant decline in the incidence of acquired immune deficiency syndrome (AIDS)-related KS with the use of highly active antiretroviral therapy (HAART), some patients, even those with a good immune restoration, still have aggressive disease. Liposomal anthracyclines or combination chemotherapy are widely used but adverse effects limit their utilization.
  
  
  OBJECTIVE
  We studied the efficacy and tolerance of docetaxel in the treatment of AIDS-related KS after pretreatment with anthracycline. PATIENTS/METHODS AND MAIN OUTCOME MEASURE: A retrospective cohort study was done. Nine human immunodeficiency virus (HIV)-infected patients were treated from 1997 to 2002 with docetaxel. Tumour response was evaluated using the AIDS Clinical Trial Group (ACTG) staging criteria. Clinical and biological toxicity was evaluated. AIDS status with HIV viral load and CD4 T-cell count were measured at the beginning and at the end of the treatment.
  
  
  RESULTS
  A major (complete or partial) response and a stabilization of the disease were demonstrated in seven and two patients, respectively. Grade 4 neutropenia and thrombocytopenia were observed in four of nine and one of nine patients, respectively. One patient died after sepsis.
  
  
  CONCLUSIONS
  Docetaxel has a good and rapid efficacy in anthracycline-pretreated patients with severe AIDS-related KS. Phase II/III trials should be done to compare docetaxel with liposomal anthracyclines as a first-line treatment.
authors.affiliation: Department of Dermatology, Bichat Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, 46 rue Henri Huchard, 75018 Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Autier
authors.forename: C
authors.initials: C
authors.lastname: Picard-Dahan
authors.forename: E
authors.initials: E
authors.lastname: Marinho
authors.forename: M
authors.initials: M
authors.lastname: Grossin
authors.forename: P
authors.initials: P
authors.lastname: Yeni
authors.forename: C
authors.initials: C
authors.lastname: Leport
authors.forename: J-L
authors.initials: JL
authors.lastname: Vildé
authors.forename: B
authors.initials: B
authors.lastname: Crickx
authors.forename: V
authors.initials: V
authors.lastname: Descamps
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000276:immunology; D000328:Adult; D018943:Anthracyclines / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D043823:Taxoids / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel